AIM ImmunoTech Inc.

AIM ImmunoTech Inc. announced a Special Meeting of Stockholders to be held virtually on July 15, 2026. Shareholders will vote on several proposals, including a potential reverse stock split of up to 1-for-25, at the Board's discretion. Additionally, the company seeks approval for the issuance of common stock exceeding 19.99% of outstanding shares related to the exercise of Class H, I, and J warrants, and the conversion of two promissory notes, all for NYSE American compliance. The Board of Directors strongly recommends voting 'FOR' all proposals.

AIM ImmunoTech Inc. highlighted significant progress in its Ampligen pancreatic cancer development program, including the early completion of Phase 2 DURIPANC study enrollment and positive interim clinical updates. The company anticipates key milestones, with primary endpoint analysis expected in December 2026 and topline results in the first quarter of 2027. AIM believes these advancements position Ampligen for potential late-stage development and represent a critical value-inflection period for the company.

AIM ImmunoTech Inc. announced that its CEO, Thomas Equels, will present at the Webull Corporate Connect Webinar Series on June 24, 2026, from 2:40 PM to 3:00 PM ET. The virtual presentation will provide an update on the immuno-pharma company, which is focused on developing Ampligen® for late-stage pancreatic cancer. This participation aims to engage with investors through Webull's leading digital investment platform, which serves over 27 million registered users.

AIM ImmunoTech Inc. announced that the final subject has received their first dose in the Phase 2 DURIPANC clinical trial, evaluating Ampligen in combination with AstraZeneca’s Imfinzi for metastatic pancreatic cancer. Primary endpoint analysis is expected to begin in December 2026, with topline results anticipated in Q1 2027. Secondary endpoint analysis, including Overall Survival (OS), is expected to start in June 2027. The company plans to use exploratory biomarker data from DURIPANC to design a Phase 3 study, focusing on identifying patient subsets most likely to benefit from Ampligen-based therapy, building on promising prior data.

AIM ImmunoTech Inc. has filed an S-1 registration statement with the SEC for the resale of up to 13,077,089 shares of its common stock by selling stockholders. These shares originate from a registered direct offering and a concurrent private placement that concluded on June 10, 2026. The filing details the various components of the offering, including PIPE shares, shares underlying pre-funded warrants, Class J warrants, and placement agent warrants. The company's common stock is traded on the NYSE American under the ticker AIM, with the last reported price being $0.40 on June 17, 2026. AIM ImmunoTech will not receive proceeds from the resale of these shares, but could potentially receive up to $5.5 million if certain warrants are exercised for cash.

AIM ImmunoTech Inc. announced it has regained compliance with NYSE American's continued listing standards related to stockholders' equity. This achievement follows a series of financing activities in May and June 2026, including a warrant exercise inducement offer and the issuance of common stock and warrants, which collectively raised approximately $8.5 million. The company now believes its stockholders' equity exceeds the $6.0 million minimum requirement, leading to the removal of the "below compliance" indicator from its trading symbol.

AIM ImmunoTech Inc. has entered into definitive agreements for a registered direct offering and a concurrent private placement, aiming to raise approximately $2.65 million in gross proceeds. The offerings include the sale of common stock, pre-funded warrants, and Class J warrants. Ladenburg Thalmann & Co. Inc. is serving as the exclusive placement agent. The net proceeds are intended for manufacturing clinical drug supply, current and planned clinical trial activities, and working capital.

AIM ImmunoTech Inc.'s Board of Directors approved an amendment to its Amended and Restated Bylaws, effective June 9, 2026. This amendment revises the voting standard for stockholder proposals, excluding the election of directors. The new standard dictates that proposals will be determined by the affirmative vote of a majority of votes cast, specifically excluding abstentions and broker non-votes, a change from the previous requirement of a majority in voting power of shares present and entitled to vote.

AIM ImmunoTech Inc. announced definitive agreements for a registered direct offering and concurrent private placement, aiming to raise approximately $2.65 million in gross proceeds. The offering, priced at-the-market, involves the sale of 2,554,119 shares of common stock in the direct offering and an equal number of unregistered shares (or pre-funded warrants) along with Class J warrants to purchase up to 10,216,476 shares in the private placement, all at $0.5189 per share. The company plans to use the net proceeds for clinical drug supply manufacturing, current and planned Phase 3 clinical trial activities, and working capital.

AIM ImmunoTech Inc. has filed an S-1 registration statement to allow selling stockholders to resell up to 31,287,933 shares of common stock. These shares are underlying various warrants issued in recent transactions, including a warrant inducement and a registered direct offering. The company itself will not receive proceeds from the resale, but could generate approximately $14.5 million if the warrants are exercised for cash. The filing also addresses the company's efforts to maintain compliance with NYSE American listing requirements, particularly regarding stockholders' equity.